AI assistant
Sending…
SOLIGENIX, INC. — Director's Dealing 2007
Aug 14, 2007
35119_dirs_2007-08-14_bf23e3de-e470-4f83-9c4a-b06eabe7f76a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2007-08-10
Reporting Person: Clavijo James (Controller/Treasurer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2007-08-10 | Stock Options (Right to Buy) | $0.47 | A | 300000 | Acquired | 2017-08-09 | Common Stock (300000) | Direct |
Footnotes
F1: The stock options were granted at an exercise price of $0.47 per share, which is a 68% premium to the Company?s common stock price of $0.28 on August 10, 2007. The stock options, which are for a term of 10 years from the date of grant and subject to earlier termination upon the occurrence of certain events related to termination of employment, vest at the rate of 25% immediately and 25% per year for 3 years.
More from SOLIGENIX, INC.
Regulatory Filings
2026
May 28
Capital/Financing Update
2026
May 28
Interim / Quarterly Report
2026
May 8
Interim / Quarterly Report
2026
May 8
Interim / Quarterly Report
2026
May 8
Capital/Financing Update
2026
May 8
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 3
Regulatory Filings
2026
Apr 3